These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16565242)

  • 21. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
    Blacklock CL; Hirst JA; Taylor KS; Stevens RJ; Roberts NW; Farmer AJ
    Diabet Med; 2011 Oct; 28(10):1182-7. PubMed ID: 21627686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials.
    Cheng J; Zhang W; Zhang XH; He Q; Tao XJ; Chen JH
    Int J Clin Pract; 2009 Jun; 63(6):880-8. PubMed ID: 19490198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
    Thomas MC; Atkins RC
    Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.
    Sun LJ; Sun YN; Shan JP; Jiang GR
    J Diabetes Investig; 2017 Jul; 8(4):609-618. PubMed ID: 28107779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH; Guan CJ; Li LY; Gan P
    Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes.
    Lewis EJ
    Am J Hypertens; 2002 Oct; 15(10 Pt 2):123S-128S. PubMed ID: 12383593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative risk of new-onset hyperkalemia for antihypertensive drugs in patients with diabetic nephropathy: A Bayesian network meta-analysis.
    Zhu S; Li J; Zhao X
    Int J Clin Pract; 2021 Aug; 75(8):e13940. PubMed ID: 33332696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ACEI and ARB Lower the Incidence of End-Stage Renal Disease among Patients with Diabetic Nephropathy: A Meta-analysis.
    Deng X; Li D; Tang Q; Chen Y
    Comput Math Methods Med; 2022; 2022():6962654. PubMed ID: 35685896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving strategies for renoprotection: diabetic nephropathy.
    Parving HH; Hovind P; Rossing K; Andersen S
    Curr Opin Nephrol Hypertens; 2001 Jul; 10(4):515-22. PubMed ID: 11458033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.
    Parving HH
    J Hypertens Suppl; 1998 Jan; 16(1):S99-101. PubMed ID: 9534107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
    Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
    Parving HH; Rossing P
    Curr Opin Nephrol Hypertens; 1994 May; 3(3):292-300. PubMed ID: 7922255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
    Tian ML; Shen Y; Sun ZL; Zha Y
    Int Urol Nephrol; 2015 May; 47(5):815-22. PubMed ID: 25862237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.